JP2006528236A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528236A5
JP2006528236A5 JP2006530660A JP2006530660A JP2006528236A5 JP 2006528236 A5 JP2006528236 A5 JP 2006528236A5 JP 2006530660 A JP2006530660 A JP 2006530660A JP 2006530660 A JP2006530660 A JP 2006530660A JP 2006528236 A5 JP2006528236 A5 JP 2006528236A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
mammal
disorder
ziprasidone
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006530660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/001600 external-priority patent/WO2004100956A1/en
Publication of JP2006528236A publication Critical patent/JP2006528236A/ja
Publication of JP2006528236A5 publication Critical patent/JP2006528236A5/ja
Pending legal-status Critical Current

Links

JP2006530660A 2003-05-16 2004-05-05 ジプラシドンを用いて認知を増強する方法 Pending JP2006528236A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47137903P 2003-05-16 2003-05-16
PCT/IB2004/001600 WO2004100956A1 (en) 2003-05-16 2004-05-05 Method for enhancing cognition using ziprasidone

Publications (2)

Publication Number Publication Date
JP2006528236A JP2006528236A (ja) 2006-12-14
JP2006528236A5 true JP2006528236A5 (enExample) 2007-06-21

Family

ID=33452442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530660A Pending JP2006528236A (ja) 2003-05-16 2004-05-05 ジプラシドンを用いて認知を増強する方法

Country Status (9)

Country Link
US (2) US20050014764A1 (enExample)
EP (1) EP1626722A1 (enExample)
JP (1) JP2006528236A (enExample)
AR (1) AR044337A1 (enExample)
BR (1) BRPI0419067A (enExample)
CA (2) CA2525323A1 (enExample)
MX (1) MXPA05012325A (enExample)
TW (1) TW200507847A (enExample)
WO (1) WO2004100956A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US20100222353A1 (en) * 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
EP2520567A3 (en) * 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
BRPI0719166A2 (pt) * 2006-10-12 2014-06-03 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (en) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
WO2009137843A2 (en) * 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
HRP20150882T1 (hr) * 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2016191316A1 (en) * 2015-05-22 2016-12-01 Stem Cell Theranostics, Inc. Modulation of drug-induced cardiotoxicity
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
TR199802241T2 (enExample) * 1996-05-07 1999-02-22 Pfizer Inc.
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
IL125951A (en) * 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6387904B2 (en) * 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
EP1165027A1 (en) * 1999-03-30 2002-01-02 Lion Corporation Hairdye composition of single preparation type containing an oxidase
WO2000059489A2 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Similar Documents

Publication Publication Date Title
JP2019031502A5 (enExample)
JP2007516193A5 (enExample)
JP2010529118A5 (enExample)
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
JP2007523049A5 (enExample)
JP2011513196A5 (enExample)
CA2256227A1 (en) Method of treating psychiatric conditions
HRP20110414T1 (hr) Indoli i njihova uporaba u liječenju
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
WO2007092329A3 (en) Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
EP1706108A4 (en) TREATMENT OF FAT AND METABOLIC SYNDROME WITH TRANSHINONE DERIVATIVES FOR INCREASING METABOLISM ACTIVITY
JP2008526861A5 (enExample)
JP2006515370A5 (enExample)
EA200900706A1 (ru) Арилвинилазациклоалкановые соединения и способы их получения и применения
EP1910321A4 (en) NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE
JP2007509960A5 (enExample)
JP2018528266A5 (enExample)
JP2008501778A5 (enExample)
JP2007516278A5 (enExample)
JP2005527477A5 (enExample)
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
DE602005002776D1 (de) Verfahren zur Herstellung von 1,3-Dihydro-2H-3-Benzazepin-2-on und Anwendung zur Herstellung von Ivabradine und ihren pharmazeutischen annehmbaren Salzen
JP2004517948A5 (enExample)
JP2007533705A5 (enExample)
JP2006505577A5 (enExample)